Core Viewpoint - Class actions have been initiated on behalf of stockholders of PomDoctor, Ltd. and Inovio Pharmaceuticals, Inc., with deadlines for lead plaintiff petitions approaching [1]. PomDoctor, Ltd. (NASDAQ:POM) - The class period for PomDoctor is from October 9, 2025, to December 11, 2025, with a lead plaintiff deadline of April 7, 2026 [4]. - The complaint alleges that PomDoctor was involved in a fraudulent stock promotion scheme, which included misinformation on social media and impersonation of financial professionals [4]. - It is claimed that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign, and that the company's public statements omitted critical information regarding false rumors and artificial trading activity [4]. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - The class period for Inovio is from October 10, 2023, to December 26, 2025, also with a lead plaintiff deadline of April 7, 2026 [4]. - The lawsuit alleges that Inovio made false statements regarding the manufacturing of its CELLECTRA device and its ability to submit a Biologics License Application (BLA) for INO-3107 to the FDA by the second half of 2024 [4]. - On December 29, 2025, the FDA accepted Inovio's BLA for INO-3107 on a standard review timeline, but noted that the company did not provide sufficient information for accelerated approval, leading to a stock price drop of $0.56 per share, or 24.45%, closing at $1.73 [4].